Of note, before treatment with anti–IL-6 mAb, a state of chronic low-grade inflammation was induced in mice administering low-dose lipopolysaccharide, to mimic the baseline conditions of patients included in the RESCUE trial, who presented chronic kidney disease and systemic inflammation as assessed by hsCRP. The gene discussed is IL6; the disease is chronic kidney disease.